Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹7,567 Cr
verified against source
Revenue YoY
10%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Aurobindo Pharma reported a solid Q1 FY25 with revenue of INR 7,567 crore (+10% YoY) and PAT of INR 919 crore (+61% YoY), driven by strong performance in Europe (EUR 221 million, +8% YoY) and growth markets (+49% YoY). US formulation revenue was $426 million (+12% YoY), supported by volume gains and new launches, though injectable sales were impacted by remediation at Eugia Unit III. EBITDA margin of 21.4% was in line with guidance, with one-off costs of ~$9 million for remediation and Pen-G ramp-up. Management reiterated FY25 EBITDA margin target of 21%-22% and expects improvement from Q2 as remediation costs decline and Pen-G ramps from October. Europe is on track to exceed EUR 880 million for FY25. Key risk: further delays in Pen-G ramp-up or injectable remediation could pressure margins.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated the internal EBITDA margin target of 21%-22% for FY25, with potential revision in Q2 call.
- Europe formulations on track to achieve EUR 880 million+ for FY25, with potential to reach EUR 900 million.
- Pen-G plant expected to ramp up significantly from October 2024, with 80% capacity utilization targeted by Q3.
- China plant expected to start commercial production from Q3 FY25, with ramp-up from Q4 FY25.
Risks flagged
- Pen-G plant faced teething problems in Q1; any further delays could impact margin improvement expectations.
- Eugia Unit III remediation cost $9M in Q1; Bhiwadi plant received OAI. Further regulatory actions could disrupt injectable sales.
- Management expects current US pricing scenario to continue; low single-digit price erosion in injectables could pressure margins.
- Biosimilar filings with EMA and FDA are subject to regulatory uncertainties; delays could push revenue contribution beyond FY26.
Key quotes
- We are confident of achieving our overall internal EBITDA margin target of around 21%-22%, as mentioned during the last earnings call.
- Our pipeline now extends up to 2032, and I'm reasonably convinced about the progress we are making.
- We have a settlement in place. Based on the settlement, we cannot launch now.
Research modules